Latest Earnings Results: Q2 '26
Estimated EPS
---
Reported EPS
-$0.35
Surprise
---
Estimated Rev
---
Reported Rev
---
Surprise
---
Brainstorm Cell Therapeutics Inc. reported a net loss of $3.855 million for the three months ended June 30, 2026, compared to a net loss of $2.903 million in the prior year.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.18 | -- | -- | N/A |
Q2 '26 | -- | -$0.35 | -- | N/A |
Q1 '26 | -- | -$0.19 | -- | N/A |
Q4 '25 | -$0.28 | -- | -- | N/A |
Q3 '25 | -$0.37 | -$0.19 | 48.65% | BEAT |